Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.
Type:
Application
Filed:
December 13, 2002
Publication date:
July 3, 2003
Applicant:
CircaGen Pharmaceutical, a Delaware corporation
Inventors:
Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L. Wiech
Abstract: Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Inhibition of histone deacetylase can lead to the histone deacetylase-mediated transcriptional repression of tumor suppressor genes. For example, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, such as hematopoiesis, and genetic related metabolic disorders, such as, cystic fibrosis and adrenoleukodystrophy.
Type:
Application
Filed:
December 2, 2002
Publication date:
May 1, 2003
Applicant:
CircaGen Pharmaceutical, a Maryland corporation
Inventors:
Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L. Wiech
Abstract: Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Inhibition of histone deacetylase can lead to the histone deacetylase-mediated transcriptional repression of tumor suppressor genes. For example, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, such as hematopoiesis, and genetic related metabolic disorders, such as, cystic fibrosis and adrenoleukodystrophy.
Type:
Grant
Filed:
March 27, 2001
Date of Patent:
December 17, 2002
Assignee:
CircaGen Pharmaceutical
Inventors:
Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L. Wiech
Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.
Type:
Application
Filed:
December 26, 2001
Publication date:
October 3, 2002
Applicant:
CircaGen Pharmaceutical, a Delaware corporation
Inventors:
Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L. Wiech